Print

IGBA identifies streamlined development through reduced comparative clinical studies and appropriate use of global comparator product as key to greater biosimilar access (July 2024)

The mandate to conduct routine comparative clinical efficacy studies for biosimilar medicines, compounded by duplicative regional requirements, serves as a barrier to greater medicine access for patients. The International Generic and Biosimilar Medicines Association (IGBA) has issued two position papers; the first proposing streamlined development through reduced clinical studies and the second proposing use of the same comparator product across jurisdictions. 

Print

IGBA Statement at the Opening of the Sessions at the WIPO Assemblies (July 2024)

Pharmaceutical innovation drives progress, and deserves reward, with intellectual property playing a key role in its protection. Expanding access to these innovations after rewarding them is crucial for public health. In well-functioning markets, generic and biosimilar medicines provide affordable, quality-assured therapeutic options enabling widespread access without compromising safety, efficacy, or quality. This balance supports Universal Health Coverage, reduces financial vulnerability, and ensures sustainable healthcare systems, contributing to Sustainable Development Goals 1, 3, and 10.

Print

IGBA Welcomes update to ICH M7 on Assessment and Control of Nitrosamine Impurities (June 2024)

The International Generic and Biosimilar Medicines Association (IGBA) commends the General Assembly of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) for its decision to develop  an Addendum to the ICH M7 Guideline on Assessment and Control of DNA Reactive (mutagenic) impurities, to incorporate the latest scientific advancements supporting the safety assessment and control of nitrosamine impurities into internationally harmonized guidance.

Share this page!

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

C/O DYN SA
Rue de Cornavin 11
1201 Geneva, Switzerland

E-mails: 
This email address is being protected from spambots. You need JavaScript enabled to view it.  
or  
Secretary General –   This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow us on: Twitter - LinkedIn - YouTube

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site